RP-2119

RP-2119 is an orally bioactive Polymerase Theta (Polθ) inhibitor, with an IC50 of 0.7 nM against human Polθ ATPase. RP-2119 reduces Polθ activity and exerts antiproliferative effects in BRCA2-deficient cancer cells. RP-2119 exhibits antitumor activity in BRCA2-deficient cancer cell xenograft mouse models. RP-2119 can be used for the research of cancer and homologous recombination-deficient cancers, including brca1/brca2-mutant cancers and shld2-mutant cancers.


Cat. No.: EX-A14068	Purity: >98%

	Chemical structure of RP-2119

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock
5mg	516	in_stock
10mg	833	in_stock
25mg	1385	in_stock
50mg	2131	in_stock
100mg	3071	in_stock

Send PO to E-mail:[email protected]; or Fax:+86 020 81619670

Discount Request


CAS No.	2922287-81-6
Purity	>98%
Formula	C24H19F2N7O2S
Mol Weight	507.515
Color	Off-white to yellow
State	Solid
Solubility	DMSO : 100 mg/mL
Shelf Life	>3 years if stored properly
Storage	Powder -20°C, 3 years , 4°C, 2 years; In solvent -20°C, 1 month.
Shipping	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Reference:	[1]. Bingcan Liu, et al. N-(5-substituted-[(I,3,4-thiadiazolyl) or(I,3-thiazolyl)](substituted)carboxamide compoundspharmaceutical compositions, and methods of preparing the amide compounds and of their use. Wo2024069592A1.2024.04.04. [2]. Mochirian P, et al. The Discovery of RP-2119: A Potent, Selective, and Orally Bioavailable Polθ ATPase Inhibitor. J Med Chem. 2025;68(18):19726-19745.
CoA	CoA of RP-2119

Smiles:	O=C(C1=C(C=C(N=C1)C2=NN(C=C2)C)C3=CC(C(F)F)=NC=C3OC)NC4=NN=C(S4)C#CC5CC5


		Search